{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:29:13Z","timestamp":1791563353541,"version":"4.3.4"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.atherosclerosis.2019.02.028","type":"journal-article","created":{"date-parts":[[2019,3,3]],"date-time":"2019-03-03T09:22:17Z","timestamp":1551604937000},"page":"66-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes"],"prefix":"10.1016","volume":"284","author":[{"given":"Fabio","family":"Nascimbeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Lugari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mondelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Onfiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Carubbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-0698","authenticated-orcid":false,"given":"Amedeo","family":"Lonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib1","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.3748\/wjg.v23.i36.6571","article-title":"Nonalcoholic fatty liver disease: evolving paradigms","volume":"23","author":"Lonardo","year":"2017","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1159\/000360510","article-title":"Non-alcoholic Fatty liver disease: diagnosis and investigation","volume":"32","author":"Nascimbeni","year":"2014","journal-title":"Dig. Dis."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/hep.22783","article-title":"Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease","volume":"49","author":"Arrese","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/17474124.2015.965143","article-title":"Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease","volume":"9","author":"Lonardo","year":"2015","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib8","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"L. European association for the study of the, D. European association for the study of, O. European association for the study of, EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib9","first-page":"17","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk","volume":"71","author":"Athyros","year":"2017","journal-title":"An Expert Panel Statement, Metabolism: Clin. Exp."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib10","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1440-1746.2012.07232.x","article-title":"Potential for statins in the chemoprevention and management of hepatocellular carcinoma","volume":"27","author":"Lonardo","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.117.027067","article-title":"Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke","volume":"136","author":"Heller","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/hep.22402","article-title":"Statins in liver disease: a molehill, an iceberg, or neither?","volume":"48","author":"Argo","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11938-018-0180-4","article-title":"The use of statins in patients with chronic liver disease and cirrhosis","volume":"16","author":"Moctezuma-Velazquez","year":"2018","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/apt.14341","article-title":"Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.29172","article-title":"Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study","volume":"66","author":"Chang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-0773.1990.tb00840.x","article-title":"Biochemical changes and morphological alterations of the liver in Guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor)","volume":"67","author":"Horsmans","year":"1990","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib18","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity: focus on patients with fatty liver","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1592\/phco.24.6.584.34738","article-title":"Statins and liver toxicity: a meta-analysis","volume":"24","author":"de Denus","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.amjmed.2006.07.033","article-title":"Impact of statin dosing intensity on transaminase and creatine kinase","volume":"120","author":"Dale","year":"2007","journal-title":"Am. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib21","first-page":"4","article-title":"The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease, Digestive and liver disease","volume":"47","author":"Pastori","year":"2015","journal-title":"Off. J. Italian Soc. Gastroenterol. Ital. Assoc. Study. Liver"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bjornsson","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bjornsson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Group for the Study of Drug-Induced Liver, Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib26","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"N. drug Induced Liver Injury, Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","author":"Russo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/liv.13308","article-title":"Hepatotoxicity of statins and other lipid-lowering agents","volume":"37","author":"Bjornsson","year":"2017","journal-title":"Liver Int. : Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","article-title":"Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians","volume":"340","author":"Rzouq","year":"2010","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ Open Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.numecd.2016.09.011","article-title":"Under-prescription of statins in patients with non-alcoholic fatty liver disease, Nutrition, metabolism, and cardiovascular diseases","volume":"27","author":"Del Ben","year":"2017","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib32","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","article-title":"Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia","volume":"61","author":"Blais","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/apt.14976","article-title":"Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany","volume":"48","author":"Labenz","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib35","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib36","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hep.21248","article-title":"Statins and hepatic steatosis: perspectives from the Dallas heart study","volume":"44","author":"Browning","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib37","first-page":"720","article-title":"Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals, Digestive and liver disease","volume":"46","author":"de Keyser","year":"2014","journal-title":"Off. J. Italian Soc. Gastroenterol. Ital. Assoc. Study. Liver"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib38","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial","volume":"102","author":"Bril","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib39","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"F. The national lipid association's statin safety task, an assessment by the statin liver safety task force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J. Clinic. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib40","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Y. Council on cardiovascular disease in the, C. Council on clinical, C. Stroke, statin safety and associated adverse events: a scientific statement from the American heart association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.numecd.2017.03.001","article-title":"Statin use and risk of new-onset diabetes: a meta-analysis of observational studies, Nutrition, metabolism, and cardiovascular diseases","volume":"27","author":"Casula","year":"2017","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib42","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/pds.4020","article-title":"Statin use and the risk of developing diabetes: a network meta-analysis","volume":"25","author":"Thakker","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib44","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjcard.2012.12.037","article-title":"Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus","volume":"111","author":"Navarese","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib45","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"Jama"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000485196","article-title":"Statins and new-onset diabetes in cardiovascular and kidney disease cohorts: a meta-analysis","volume":"8","author":"Kamran","year":"2018","journal-title":"Cardiorenal medicine"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.atherosclerosis.2005.08.021","article-title":"Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients","volume":"184","author":"Antonopoulos","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib48","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.metabol.2008.07.030","article-title":"Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia","volume":"57","author":"Hyogo","year":"2008","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0032-1306423","article-title":"Dyslipidemia in patients with nonalcoholic fatty liver disease","volume":"32","author":"Chatrath","year":"2012","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib50","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib51","doi-asserted-by":"crossref","first-page":"G407","DOI":"10.1152\/ajpgi.00441.2016","article-title":"Rationale for the use of statins in liver disease","volume":"312","author":"Schierwagen","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2019.02.028_bib52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12325-016-0306-9","article-title":"The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans","volume":"33","author":"Ballestri","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/17474124.2018.1415756","article-title":"Clinical relevance of liver histopathology and different histological classifications of NASH in adults","volume":"12","author":"Nascimbeni","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/17474124.2018.1439379","article-title":"The potential role of statins in treating liver disease","volume":"12","author":"Imprialos","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.01.008","article-title":"Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study","volume":"174","author":"Rallidis","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study","volume":"47","author":"Ekstedt","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib58","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib59","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1872-034X.2011.00849.x","article-title":"Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study","volume":"41","author":"Hyogo","year":"2011","journal-title":"Hepatol. Res. Off. J. Japan Soc. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib60","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1872-034X.2012.01034.x","article-title":"Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study","volume":"42","author":"Nakahara","year":"2012","journal-title":"Hepatol. Res. Off. J. Japan Soc. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib61","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib62","series-title":"Statins for Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis","first-page":"CD008623","author":"Eslami","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib63","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib65","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.22570","article-title":"Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A","volume":"49","author":"Rodriguez-Calvo","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbalip.2017.12.002","article-title":"Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins, Biochimica et biophysica acta","volume":"1863","author":"Zhang","year":"2018","journal-title":"Molecular and cell biology of lipids"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib67","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.bbalip.2017.09.007","article-title":"Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5, Biochimica et biophysica acta","volume":"1862","author":"Gao","year":"2017","journal-title":"Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib68","doi-asserted-by":"crossref","first-page":"35732","DOI":"10.1038\/srep35732","article-title":"SREBP-2\/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/092986707779313381","article-title":"Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins","volume":"14","author":"Lahera","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib70","first-page":"41","article-title":"Statins and oxidative stress in chronic heart failure, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese","volume":"35","author":"Costa","year":"2016","journal-title":"J. Cardiol.: an official journal of the Portuguese Society of Cardiology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib71","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/hep.28616","article-title":"Statins in cirrhosis: the magic pill?","volume":"63","author":"Malizia","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1254\/jphs.92.7","article-title":"The regulation of ICAM-1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses","volume":"92","author":"Nishibori","year":"2003","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib73","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/thx.2005.057976","article-title":"Potential therapeutic role for statins in respiratory disease","volume":"61","author":"Hothersall","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib74","first-page":"492","article-title":"Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-alpha-lowering property, Digestive and liver disease","volume":"44","author":"Hyogo","year":"2012","journal-title":"Off. J. Italian Soc. Gastroenterol. Ital. Assoc. Study. Liver"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib75","doi-asserted-by":"crossref","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bjp.0704678","article-title":"Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ","volume":"136","author":"Wagner","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib77","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/BF02256431","article-title":"HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages","volume":"10","author":"Huang","year":"2003","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib78","doi-asserted-by":"crossref","first-page":"G147","DOI":"10.1152\/ajpgi.00462.2007","article-title":"Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver","volume":"296","author":"Moreno","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib79","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1476-5381.2008.00043.x","article-title":"Simvastatin protects against cholestasis-induced liver injury","volume":"156","author":"Dold","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib80","first-page":"1440","article-title":"Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats, Laboratory investigation","volume":"92","author":"Klein","year":"2012","journal-title":"a journal of technical methods and pathology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib81","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins","volume":"58","author":"Marrone","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12876-015-0248-8","article-title":"Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells","volume":"15","author":"Chong","year":"2015","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib83","first-page":"381","article-title":"Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFbeta1\/Smad3 pathway, Digestive and liver disease","volume":"50","author":"Cheng","year":"2018","journal-title":"Off. J. Italian Soc. Gastroenterol. Ital. Assoc. Study. Liver"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib84","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.3748\/wjg.v22.i27.6201","article-title":"Pleiotropic effects of statins in the diseases of the liver","volume":"22","author":"Janicko","year":"2016","journal-title":"World J. Gastroenterol. : WJG"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib85","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib86","first-page":"957","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial, Digestive and liver disease","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Off. J. Italian Soc. Gastroenterol. Ital. Assoc. Study. Liver"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib87","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib88","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/ajg.2017.170","article-title":"Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis","volume":"112","author":"Kamal","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib89","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol. : the official clinical practice journal of the American Gastroenterological Association"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib90","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005399","article-title":"Statin use and risk of liver cancer: an update meta-analysis","volume":"4","author":"Shi","year":"2014","journal-title":"BMJ open"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib92","doi-asserted-by":"crossref","first-page":"21753","DOI":"10.18632\/oncotarget.7832","article-title":"Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib93","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jhep.2017.10.018","article-title":"Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study","volume":"68","author":"Kim","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib94","doi-asserted-by":"crossref","first-page":"e4639","DOI":"10.1097\/MD.0000000000004639","article-title":"Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients","volume":"95","author":"Wu","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib95","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.surg.2017.09.026","article-title":"Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: a subgroup analysis of patients without chronic hepatitis viral infection","volume":"163","author":"Nishio","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib96","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/lt.25067","article-title":"Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the","volume":"24","author":"Patel","year":"2018","journal-title":"Int. Liver Transplant. Soc."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib97","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4254\/wjh.v8.i22.924","article-title":"Cholesterol metabolism in cholestatic liver disease and liver transplantation: from molecular mechanisms to clinical implications","volume":"8","author":"Nemes","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib98","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0168-8278(01)00044-7","article-title":"Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial","volume":"35","author":"Zachoval","year":"2001","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib99","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1399-0012.2007.00780.x","article-title":"Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients","volume":"22","author":"Martin","year":"2008","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib100","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib101","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats","volume":"46","author":"Abraldes","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib102","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib103","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1136\/gutjnl-2014-308800","article-title":"Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension","volume":"64","author":"Trebicka","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib104","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib105","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib106","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3892\/ijo.2010.892","article-title":"Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK","volume":"38","author":"Relja","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib107","doi-asserted-by":"crossref","first-page":"14573","DOI":"10.1038\/srep14573","article-title":"Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension","volume":"5","author":"Uschner","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib108","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5604\/01.3001.0011.7394","article-title":"Potential molecular targets of statins in the prevention of hepatocarcinogenesis","volume":"17","author":"Ridruejo","year":"2018","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib109","article-title":"An evidence-based review of statin use in patients with nonalcoholic fatty liver disease, clinical medicine insights","volume":"11","author":"Sigler","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2019.02.028_bib110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.atherosclerosis.2017.10.030","article-title":"Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis","volume":"267","author":"Hoeke","year":"2017","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915019301169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915019301169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:38:55Z","timestamp":1758155935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915019301169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":110,"alternative-id":["S0021915019301169"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.02.028","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}